10x Genomics Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
1,178
- Stock Symbol
-
TXG
- Investments
-
8
- Share Price
-
$57.40
- (As of Thursday Closing)
10x Genomics General Information
Description
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Contact Information
Website
www.10xgenomics.comCorporate Office
- 6230 Stoneridge Mall Road
- Pleasanton, CA 94588-3260
- United States
Corporate Office
- 6230 Stoneridge Mall Road
- Pleasanton, CA 94588-3260
- United States
10x Genomics Stock Performance
As of 19-Nov-2026, 10x Genomics’s stock price is $57.40. Its current market cap is $7.55B with 132M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $57.40 | $57.07 | $15.18 - $102.81 | $7.55B | 132M | 3.36M | -$0.52 |
10x Genomics Financials Summary
As of 30-Sep-2026, 10x Genomics has a trailing 12-month revenue of $619M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 11,299,873 | 1,668,981 | 1,426,059 | 6,356,519 |
| Revenue | 618,576 | 642,823 | 610,785 | 618,727 |
| EBITDA | (39,587) | (16,139) | (152,918) | (221,996) |
| Net Income | (67,078) | (43,544) | (182,627) | (255,099) |
| Total Assets | 1,063,129 | 1,041,365 | 918,636 | 965,143 |
| Total Debt | 75,792 | 84,361 | 82,613 | 95,370 |
10x Genomics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
10x Genomics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
10x Genomics Comparisons
Industry
Financing
Details
10x Genomics Competitors (21)
One of 10x Genomics’s 21 competitors is Bio-Techne, a Corporation company based in Minneapolis, MN.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bio-Techne | Corporation | Minneapolis, MN | ||||
| Standard BioTools | Formerly VC-backed | Boston, MA | ||||
| CD Genomics | Corporation | Shirley, NY | ||||
| GSK | Corporation | London, United Kingdom | ||||
| Qiagen | Formerly VC-backed | Hilden, Germany |
10x Genomics Patents
10x Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260308572-A1 | Analysis of cellular samples | Pending | 02-Apr-2025 | ||
| US-20260258490-A1 | Methods and compositions for probe rescue | Pending | 03-Mar-2025 | ||
| WO-2026178257-A1 | De-crosslinking for multi analyte analysis | Pending | 20-Feb-2025 | ||
| WO-2026165121-A1 | Rolling circle methods using primers binding to barcode sequences for amplification and related compositions | Pending | 29-Jan-2025 | ||
| WO-2026148062-A2 | Compositions and methods for analysis of cellular analytes | Pending | 31-Dec-2024 | C12Q1/6841 |
10x Genomics Signals
10x Genomics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
10x Genomics Investments & Acquisitions (8)
10x Genomics’s most recent deal was a Merger/Acquisition with Proteintech (Proteintech Genomics). The deal was made on 09-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Proteintech (Proteintech Genomics) | 09-Jun-2026 | Merger/Acquisition | Biotechnology | ||
| Scale Biosciences | 11-Aug-2025 | Merger/Acquisition | Biotechnology | ||
| Centrillion Technologies (Certain Intangible and Other Assets) | 14-Jul-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Tetramer Shop | 08-Jan-2021 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
| ReadCoor | 13-Oct-2020 | Merger/Acquisition | Discovery Tools (Healthcare) |
10x Genomics ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
20.4 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
10x Genomics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Scale Biosciences | San Diego, CA | 2020 |
10x Genomics FAQs
-
When was 10x Genomics founded?
10x Genomics was founded in 2012.
-
Where is 10x Genomics headquartered?
10x Genomics is headquartered in Pleasanton, CA.
-
What is the size of 10x Genomics?
10x Genomics has 1,178 total employees.
-
What industry is 10x Genomics in?
10x Genomics’s primary industry is Biotechnology.
-
Is 10x Genomics a private or public company?
10x Genomics is a Public company.
-
What is 10x Genomics’s stock symbol?
The ticker symbol for 10x Genomics is TXG.
-
What is the current stock price of 10x Genomics?
As of 19-Nov-2026 the stock price of 10x Genomics is $57.40.
-
What is the current market cap of 10x Genomics?
The current market capitalization of 10x Genomics is $7.55B.
-
What is 10x Genomics’s current revenue?
The trailing twelve month revenue for 10x Genomics is $619M.
-
Who are 10x Genomics’s competitors?
Bio-Techne, Standard BioTools, CD Genomics, GSK, and Qiagen are some of the 21 competitors of 10x Genomics.
-
What is 10x Genomics’s annual earnings per share (EPS)?
10x Genomics’s EPS for 12 months was -$0.52.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process